Related Experiment Videos
[Anticoagulants in the elderly. Indications]
A Gentric1, F Couturaud, D Mottier
1Service de Médecine interne gériatrique, Hôptital de la Cavale Blanche, Brest.
Insights
Anticoagulant therapy benefits are proven, but elderly patients require careful risk-benefit assessment due to higher bleeding risks. New approaches aim to improve safety and efficacy in this population.
Area of Science:
- Geriatric Medicine
- Pharmacology
- Clinical Trials
Context:
- Anticoagulant treatments are established for venous thromboembolism and atrial fibrillation in specific populations.
- Limited clinical trials focus on elderly subjects, who face increased thrombosis and bleeding risks.
- Extrapolating data from younger populations to the elderly is unreliable due to physiological differences.
Purpose:
- To emphasize the need for individualized risk-benefit assessments in elderly patients undergoing anticoagulant therapy.
- To highlight the inadequacy of current data for guiding anticoagulant use in geriatric populations.
- To advocate for tailored evaluation systems for elderly individuals to optimize treatment decisions and minimize hemorrhage risk.
Summary:
- Established anticoagulant treatments have proven benefits but require careful consideration in elderly patients.
- Elderly individuals exhibit a higher risk of both thrombosis and bleeding complications from anticoagulation.
- Individualized risk-benefit evaluations using geriatric-specific assessment tools are crucial for safe and effective anticoagulation in older adults.
Impact:
- Promotes the development of specialized anticoagulation clinics and geriatric-focused clinical trials.
- Encourages the creation of new oral anticoagulants with simplified monitoring requirements for the elderly.
- Aims to reduce therapeutic risks while maintaining or improving anticoagulant benefits in the geriatric population.
Unlabelled:
RISK AND BENEFIT: The beneficial effect of anticoagulant treatment is well established by numerous therapeutic trials demonstrating its usefulness in two main indications (venous thromboembolism and complete arrhythmia due to atrial fibrillation) in selected populations. Very few trials have been specifically conducted in elderly subjects and the increased risk of thrombosis and anticoagulant related bleeding cannot be used to extrapolate the results to elderly subjects. For this reason, a careful assessment of the initial risk and expected benefit must be made for each individual patient using a validated and systematic global evaluation system adapted for elderly subjects in order to better discern the indications and the risk of hemorrhage.
Perspectives:
The development of anticoagulation clinics, based on the method initiated by Professor Boneu at Toulouse, together with clinical trials designed to produce results transposable to the diverse and complex geriatric population, and finally the development of new oral compounds not requiring laboratory tests under the same conditions should help reduce the therapeutic risk for an equivalent benefit.